<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ethinyl estradiol and norelgestromin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ethinyl estradiol and norelgestromin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ethinyl estradiol and norelgestromin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8687" href="/d/html/8687.html" rel="external">see "Ethinyl estradiol and norelgestromin: Drug information"</a> and <a class="drug drug_patient" data-topicid="12450" href="/d/html/12450.html" rel="external">see "Ethinyl estradiol and norelgestromin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708764"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cigarette smoke and serious cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, combination hormonal contraceptives, including norelgestromin/ethinyl estradiol, are contraindicated in women who are over 35 years of age and smoke.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Obesity and venous thromboembolism risk</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Norelgestromin/ethinyl estradiol is contraindicated in women with a BMI ≥30 kg/m<sup>2</sup>. The risk of venous thromboembolism may be greater with norelgestromin/ethinyl estradiol in women with a BMI ≥30 kg/m<sup>2 </sup>compared to women with a lower BMI.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F168398"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xulane;</li>
<li>Zafemy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866825"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Evra</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1012735"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Contraceptive</span>;</li>
<li>
<span class="list-set-name">Estrogen and Progestin Combination</span></li></ul></div>
<div class="block dop drugH1Div" id="F168410"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0727c03-067f-4ea1-a1d7-d223979be587">Contraception in patients with BMI &lt;30 kg/m<sup>2</sup></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception in patients with BMI &lt;30 kg/m<sup>2</sup>:</b> Postmenarche patients: Topical: 1 patch every 7 days (once weekly) for 3 weeks (21 total days); followed by 1 week that is patch-free. Each patch should be applied on the same day each week ("patch change day") and only 1 patch should be worn at a time. No more than 7 days should pass during the patch-free interval.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients not currently using a hormonal contraceptive:</p>
<p style="text-indent:-2em;margin-left:6em;">Day 1 start: Dose starts on first day of menstrual cycle, applying 1 patch during the first 24 hours of menstrual cycle. Each patch change will then occur on that same day of the week. If the first patch is applied after the first 24 hours of menstruation, <b>an additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Sunday start: Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, apply 1 patch that very same day. <b>With a Sunday start, an additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration unless the menstrual period starts on Sunday.</b> Each patch change will then occur on Sunday.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients currently using contraception and switching to ethinyl estradiol/norelgestromin patch:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Patients Switching From Another Contraceptive Method to the Ethinyl Estradiol/Norelgestromin Patch</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Current Method</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Instructions for Switching to Patch</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Combination hormonal contraceptive, oral (oral CHC)</p></td>
<td align="left">
<p style="text-indent:0em;">Complete the current oral CHC cycle and apply the first ethinyl estradiol/norelgestromin patch on the day the next oral CHC cycle would be started.</p>
<p style="text-indent:0em;margin-top:2em;">If there is no menstrual bleeding within 7 days after taking the last active oral CHC, the patient can initiate the first patch application; however, assess pregnancy status<i>.</i></p>
<p style="text-indent:0em;margin-top:2em;">If the patch is applied &gt;1 week after taking the last active pill, <b>a nonhormonal backup contraception should be used for the first 7 days of patch use</b>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Implant</p></td>
<td align="left">
<p style="text-indent:0em;">Apply the first ethinyl estradiol/norelgestromin patch on the day the implant is removed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Injection</p></td>
<td align="left">
<p style="text-indent:0em;">Apply the first ethinyl estradiol/norelgestromin patch on the day the next injection would normally occur.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Intrauterine system (IUS)</p></td>
<td align="left">
<p style="text-indent:0em;">Apply the first ethinyl estradiol/norelgestromin patch on the day the IUS is removed.</p>
<p style="text-indent:0em;margin-top:2em;">If the IUS is not removed on the first day of the menstrual cycle, <b>a nonhormonal backup contraception should be used for the first 7 days of patch use</b>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Progestin-only pill</p></td>
<td align="left">
<p style="text-indent:0em;">Apply the first ethinyl estradiol/norelgestromin patch on the day the next progestin-only pill cycle would normally start.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Transdermal system</p></td>
<td align="left">
<p style="text-indent:0em;">Complete the current transdermal system cycle and apply the first ethinyl estradiol/norelgestromin patch on the day the next transdermal system would be applied.</p>
<p style="text-indent:0em;margin-top:2em;">If there is no menstrual bleeding within 7 days after removing the previous transdermal system, the patient can initiate the first patch application; however, assess pregnancy status<i>.</i></p>
<p style="text-indent:0em;margin-top:2em;">If the patch is applied &gt;1 week after removing the last patch, <b>a nonhormonal backup contraception should be used for the first 7 days of patch use</b>.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Vaginal ring</p></td>
<td align="left">
<p style="text-indent:0em;">Complete the current vaginal ring cycle and apply the first ethinyl estradiol/norelgestromin patch on the day the next vaginal ring would be inserted.</p>
<p style="text-indent:0em;margin-top:2em;">If there is no menstrual bleeding within 7 days after removing the vaginal ring, the patient can initiate the first patch application; however, assess pregnancy status.</p>
<p style="text-indent:0em;margin-top:2em;">If the patch is applied &gt;1 week after removing the vaginal ring, <b>a nonhormonal backup contraception should be used for the first 7 days of patch use</b>.</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109842"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution and monitor blood pressure closely.</p></div>
<div class="block dohp drugH1Div" id="F51109843"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Contraindicated in patients with hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F168402"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8687" href="/d/html/8687.html" rel="external">see "Ethinyl estradiol and norelgestromin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0727c03-067f-4ea1-a1d7-d223979be587">Contraception in patients with BMI &lt;30 kg/m<sup>2</sup></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception in patients with BMI &lt;30 kg/m<sup>2</sup>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical: </b>Apply 1 patch each week for 3 weeks (21 total days); followed by 1 week that is patch-free. Each patch should be applied on the same day each week (“patch change day”) and only 1 patch should be worn at a time. No more than 7 days should pass during the patch-free interval.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients not currently using a hormonal contraceptive:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b> Note:</b> If reasonably sure the patient is not pregnant, may be initiated at any time during the menstrual cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27467319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27467319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1 start: Dose starts on first day of menstrual cycle, applying 1 patch during the first 24 hours of menstrual cycle. Each patch change will then occur on that same day of the week. If the first patch is applied after the first 24 hours of menstruation, <b>an additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration.</b></p>
<p style="text-indent:-2em;margin-left:8em;">Quick start: Start on the day the patient receives the prescription (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23153903','lexi-content-ref-23235628','lexi-content-ref-23153901']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23153903','lexi-content-ref-23235628','lexi-content-ref-23153901'])">Ref</a></span>). <b>If initiated &gt;5 days after the onset of menses, use an additional method of contraception (nonhormonal) until 7 days of consecutive administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27467319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27467319'])">Ref</a></span>).</b></p>
<p style="text-indent:-2em;margin-left:8em;">Sunday start: Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, apply one patch that very same day. <b>With a Sunday start, an additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration unless the menstrual period starts on Sunday.</b> Each patch change will then occur on Sunday.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Patients</b>
<b> Switching From Another Contraceptive Method</b>
<b> to the Ethinyl Estradiol/Norelgestromin Patch</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Current </b>
<b>method</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Instructions for switching</b>
<b> to patch</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Combination hormonal contraceptive, oral (oral CHC)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complete the current oral CHC cycle and apply the first ethinyl estradiol/norelgestromin patch on the day the next oral CHC cycle would be started.</p>
<p style="text-indent:0em;text-align:left;">If there is no menstrual bleeding within 7 days after taking the last active oral CHC, the patient can initiate the first patch application; however, assess pregnancy status<i>.</i></p>
<p style="text-indent:0em;text-align:left;">If the patch is applied &gt;1 week after taking the last active pill, <b>use a nonhormonal back-up contraception for the first 7 days of patch use.</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Implant</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Apply the first ethinyl estradiol/norelgestromin patch on the day the implant is removed.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Injection</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Apply the first ethinyl estradiol/norelgestromin patch on the day the next injection would normally occur.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Intrauterine system (IUS)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Apply the first ethinyl estradiol/norelgestromin patch on the day the IUS is removed.</p>
<p style="text-indent:0em;text-align:left;">If the IUS is not removed on the first day of the menstrual cycle<b>, use a nonhormonal back-up contraception for the first 7 days of patch use</b>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Progestin-only pill</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Apply the first ethinyl estradiol/norelgestromin patch on the day the next progestin-only pill cycle would normally start.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Transdermal system</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complete the current transdermal system cycle and apply the first ethinyl estradiol/norelgestromin patch on the day the next transdermal system would be applied.</p>
<p style="text-indent:0em;text-align:left;">If there is no menstrual bleeding within 7 days after removing the previous transdermal system, the patient can initiate the first patch application; however, assess pregnancy status<i>.</i></p>
<p style="text-indent:0em;text-align:left;">If the patch is applied &gt;1 week after removing the last patch, <b>use a nonhormonal back-up contraception for the first 7 days of patch use</b>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Vaginal ring</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complete the current vaginal ring cycle and apply the first ethinyl estradiol/norelgestromin patch on the day the next vaginal ring would be inserted.</p>
<p style="text-indent:0em;text-align:left;">If there is no menstrual bleeding within 7 days after removing the vaginal ring, the patient can initiate the first patch application; however, assess pregnancy status</p>
<p style="text-indent:0em;text-align:left;">If the patch is applied &gt;1 week after removing the vaginal ring, <b>use a nonhormonal back-up contraception for the first 7 days of patch use</b>.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Use after childbirth: </b>Therapy should not be started &lt;4 weeks after childbirth. Pregnancy should be ruled out prior to treatment if postpartum menstrual periods have not restarted. <b>An additional method of contraception (nonhormonal) should be used for the first 7 days of consecutive administration.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Use after abortion or miscarriage:</b> Therapy may be started immediately if abortion/miscarriage occurs within the first trimester. If therapy is not started within 5 days, follow instructions for first time use; an additional method of contraception (nonhormonal) should be used for the first 7 days of consecutive administration. If abortion/miscarriage occurs during the second trimester, therapy should not be started for at least 4 weeks due to the increased risk of thromboembolic disease.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990256"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturers labeling (has not been studied); use with caution and monitor blood pressure closely.</p></div>
<div class="block doha drugH1Div" id="F50987422"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Contraindicated in patients with hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F168368"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. The following reactions have been reported with the contraceptive patch. Adverse reactions associated with oral combination hormonal contraceptive agents are also likely to appear with the topical contraceptive patch (frequency difficult to anticipate). See individual oral contraceptive monographs for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Breast changes (22%; including breast engorgement, discomfort, mastalgia)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site reaction (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (&lt;3%), pulmonary embolism (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anxiety (≤6%), mood disorder (≤6%), dizziness (3%), fatigue (3%), migraine (3%), insomnia (&lt;3%), malaise (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (3%), pruritus (3%), chloasma (&lt;3%), contact dermatitis (&lt;3%), erythema (&lt;3%), skin irritation (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Menstrual disease (6%), weight gain (3%), change in libido (&lt;3%), dyslipidemia (&lt;3%), fluid retention (&lt;3%), galactorrhea (&lt;3%), premenstrual syndrome (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (8%), vomiting (5%), diarrhea (4%), abdominal distention (&lt;3%), cholecystitis (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (8%), vaginal hemorrhage (6%), vulvovaginal candidiasis (4%), genital discharge (&lt;3%), uterine spasm (&lt;3%), vaginal dryness (&lt;3%), vulvar dryness (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (&lt;3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Alopecia, altered serum glucose, arterial thrombosis, benign mammary fibroadenoma, blood cholesterol abnormal, cerebrovascular accident, cervical dysplasia, cholelithiasis, cholestasis, cholestatic jaundice, colitis, contact lens intolerance (or complication), decreased lactation, deep vein thrombosis, dermatological reaction, dysgeusia, eczema, edema, emotional disturbance, erythema multiforme, erythema nodosum, hepatic adenoma, hepatic neoplasm, hyperglycemia, hyperirritability, hypersensitivity reaction, hypertension, hypertensive crisis, increased appetite, increased LDL cholesterol, insulin resistance, intracranial hemorrhage, irritability, lesion (hepatic), malignant neoplasm of breast, malignant neoplasm of cervix, mass (breast), migraine (with aura), myocardial infarction, outbursts of anger, seborrheic dermatitis, skin photosensitivity, skin rash, thrombosis, urticaria, uterine fibroids</p></div>
<div class="block coi drugH1Div" id="F168381"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Breast cancer (current or a history of; may be hormonal-sensitive), BMI ≥30 kg/m<sup>2</sup>, hepatic tumors (benign or malignant) or hepatic disease, pregnancy, undiagnosed abnormal uterine bleeding; use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Use is also contraindicated in patients at high risk of arterial or venous thromboembolic events for example, patients with: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, deep vein thrombosis or pulmonary embolism (current or history of), hypercoagulopathies (inherited or acquired), hypertension (uncontrolled), headaches with focal neurological symptoms, migraine headaches with aura or migraine headaches if &gt;35 years of age, thrombogenic valvular or rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation), patients &gt;35 years of age who smoke.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian-labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to ethinyl estradiol, norelgestromin, or any component of the formulation; myocardial infarction (current or history of); steroid dependent jaundice, cholestatic jaundice, or history of jaundice of pregnancy; any ocular lesion due to ophthalmic vascular disease including partial or complete loss of vision or defect in visual fields; persistent blood pressure ≥160 mm Hg systolic or ≥100 mm Hg diastolic; severe dyslipoproteinemia; women with hereditary or acquired predisposition for venous or arterial thrombosis (eg, Factor V Leiden mutation and activated protein C [APC-] resistance, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia [eg, due to MTHFR C677T, A1298 mutations], prothrombin mutation G20210A, and antiphospholipid-antibodies [anticardiolipin antibodies, lupus anticoagulant]); major surgery associated with an increased risk of post-operative thromboembolism; prolonged immobilization; coadministration with paritaprevir, ritonavir, ombitasvir (with or without dasabuvir).</p></div>
<div class="block war drugH1Div" id="F168366"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding irregularities: Amenorrhea, spotting, and unscheduled bleeding may occur, primarily during the first 3 months of therapy. Evaluate unscheduled or breakthrough bleeding that persists more than a few cycles to rule out malignancy or pregnancy. Amenorrhea or oligomenorrhea may occur after discontinuing combination hormonal contraceptives, especially when such a condition was preexistent.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cervical cancer: The use of combination hormonal contraceptives has been associated with a slight increased risk of cervical cancer; however, studies are not consistent and the risk may be related to the specific histologic type of cervical cancer, duration of contraceptive use, and other factors (Asthana 2020; Gadducci 2020). Theoretically, use may affect prognosis of existing disease. Patients awaiting treatment for cervical cancer may use combination hormonal contraceptives (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Chloasma: Combination hormonal contraceptives, as well as sun exposure and pregnancy, are triggers for chloasma. Avoid sun exposure or ultraviolet radiation during therapy in patients with a susceptibility to chloasma or additional risk factors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholestasis: Risk of cholestasis may be increased with previous cholestasis of pregnancy or cholestasis with prior oral contraceptive use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic adenomas or carcinomas: Use of combination hormonal contraceptives is associated with hepatic adenomas (rare); rupture may cause fatal intra-abdominal hemorrhage. Long-term use may be associated with an increased risk of hepatocellular carcinoma (rare).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: Combination hormonal contraceptives may adversely affect lipid levels, including serum triglycerides. Patients with hypertriglyceridemia or a family history of hypertriglyceridemia may be at increased risk of pancreatitis when using combination hormonal contraceptives. Consider alternative contraception for patients with uncontrolled dyslipidemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal thrombosis: Discontinue if unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions occur and immediately evaluate for retinal thrombosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic disorders: Higher estrogen exposure may increase the risk of adverse reactions, including venous thromboembolism (VTE). The AUC for ethinyl estradiol is ~60% higher following use of the patch than with oral tablets containing ethinyl estradiol 35 mcg. Peak concentrations are lower with the patch. Discontinue use of combination hormonal contraceptives if an arterial or venous thromboembolic event occurs. The increased risk of VTE associated with combination hormonal contraceptives is greatest during first year of use and less than the risk associated with pregnancy; some studies suggest this risk may be higher in preparations with third- or fourth-generation progestins and/or high-dose ethinyl estradiol. Patients with inherited thrombophilias (eg, protein C or S deficiency, factor V Leiden mutation, prothrombin mutation, antithrombin deficiency) may have increased risk of VTE. Age &gt;35 years, hypertension, obesity, and tobacco use also increase the risk of thromboembolic events in patients taking combination hormonal contraceptives (ASRM 2017; CDC [Curtis 2016b]). Combination hormonal contraceptives may also increase the risk of arterial thrombosis (eg, myocardial infarction, stroke); do not use in patients with a history of stroke or ischemic heart disease (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Fertility is increased following bariatric surgery. All available forms of contraception can be considered following bariatric surgery, considering the patient's body weight and time since surgery. However, long acting reversible non-oral contraceptives (eg, implants, intrauterine devices) may be preferred. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy both have the potential to expedite transit through the small bowel. RYGB may not significantly alter the absorption of oral estrogen or progestins (limited evidence following a single dose). However, gastric and small bowel transit is not well studied following chronic oral dosing; therefore, contraceptive efficacy cannot be guaranteed. Oral contraceptives may be used in patients having adjustable gastric banding unless there is diarrhea or vomiting. Reliable contraception using oral contraceptives cannot be guaranteed following jejunoileal (JI) bypass, biliopancreatic diversion (BPD), single anastomosis duodeno-ilial bypass (SADI), or omega-loop gastric bypass. Discontinue estrogen-containing birth control at least 4 weeks prior to bariatric surgery and resume no earlier than 4 weeks after surgery to minimize risk of VTE (Ciangura 2019; Mechanick 2020; Moreira de Brito 2020; Shawe 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Available studies have not shown a consistent association with combination hormonal contraceptives and breast cancer risk. Multiple studies have shown no association in current or ever users (current or past); other studies have shown a small increased risk in current users (higher risk in current users with longer durations of use) and recent users (&lt;6 months since last use). In patients at risk for breast cancer due to family history or susceptibility genes (<i>BRCA1</i>, <i>BRCA2</i>), it is unclear if combination hormonal contraceptives increase the risk for breast cancer. However, breast cancer is a hormonal-sensitive tumor and the prognosis for patients with a current or recent history of breast cancer may be worse with combination hormonal contraceptive use (CDC [Curtis 2016b]; SGO/ASRM [Chen 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with risk factors for cardiovascular disease (eg, hypertension, low HDL, high LDL, high triglycerides, older age, diabetes, patients who smoke); use of combination hormonal contraceptives may increase the risk of cardiovascular disease (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Use with caution in patients with a history of depression; discontinue if serious depression recurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: May impair glucose tolerance; use caution in patients with diabetes or prediabetes. In general, use of combination oral contraceptives has limited effects on daily insulin needs and no long-term effects on diabetes control in patients with nonvascular disease. Evaluate contraceptive use in patients with concomitant nephropathy, neuropathy, retinopathy, other vascular diseases, or diabetes &gt;20 years' duration based on the severity of the condition (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial cancer: The risk of endometrial cancer is decreased in patients using combination hormonal contraceptives. Patients awaiting treatment for endometrial cancer may use combination hormonal contraceptives (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: Combination hormonal contraceptives may cause a small increased risk of gallbladder disease or may worsen existing gallbladder disease (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Contraceptive steroids may be poorly metabolized in patients with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal. Consider use of combination hormonal contraceptives in patients with mild (compensated) cirrhosis; do not use in patients with severe (decompensated) cirrhosis (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis: Initiation of combination hormonal contraceptives is not recommended in patients with acute viral hepatitis or during a flare. Continued use in patients with chronic hepatitis has not been shown to increase the rate or severity of cirrhotic fibrosis or hepatocellular carcinoma. Continuation of use in patients who are carriers has not been shown to trigger liver failure or severe hepatic dysfunction (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary angioedema: Estrogens may induce or exacerbate symptoms in patients with hereditary angioedema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: The risk of hypertension may be increased with age, dose, and duration of use. Do not use combination hormonal contraceptives in patients with hypertension and vascular disease, or persistent BP values ≥160 mm Hg systolic or ≥100 mm Hg diastolic. The risks of use may not outweigh the benefits of treatment in patients with less severe hypertension (140 to 159 mm Hg systolic or 90 to 99 mm Hg diastolic) or those with hypertension that is adequately controlled (CDC [Curtis 2016a]). Consider other risk factors for cardiovascular disease (eg, older age, smoking, diabetes) when prescribing contraceptives (CDC [Curtis 2016b]). Monitor BP in patients with well-controlled hypertension; discontinue therapy if BP rises significantly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Evaluate new, recurrent, severe or persistent headaches. Use of combination hormonal contraceptives may be considered in patients who have migraines without aura (including menstrual migraines) (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: The risk of ovarian cancer is decreased in patients using combination hormonal contraceptives (CDC [Curtis 2016b]; SGO/ASRM [Chen 2019]). Oral contraceptives may be used to reduce the risk of ovarian cancer in at-risk patients with <i>BRCA1</i> and <i>BRCA2</i> mutations who do not have a personal history of breast cancer (SGO/ASRM [Chen 2019]). Patients awaiting treatment for ovarian cancer may use combination hormonal contraceptives (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Solid organ transplant: Use of combination hormonal contraceptives is not recommended in patients with complicated organ transplants; although data are limited, serious medical complications have been reported (eg, graft failure, rejection, cardiac allograft vasculopathy) requiring discontinuation of the contraceptive (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus: Patients with systemic lupus erythematosus (SLE) are at an increased risk for heart disease, stroke, and VTE. Do not use combination hormonal contraceptives in patients with SLE who have positive (or unknown) antiphospholipid antibodies, due to an increased risk of arterial and venous thrombosis (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Testosterone: All available forms of contraception can be considered for patients receiving gender-affirming testosterone therapy after evaluating patient preferences and medical conditions (Bonnington 2020; Krempasky 2020). However, it has been suggested to use products containing lower daily doses of ethinyl estradiol (0.01 to 0.02 mg) to decrease the risk of possible adverse reactions when testosterone therapy is used with combination hormonal contraceptives (Bonnington 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Body weight: The risk of VTE may be greater with norelgestromin/ethinyl estradiol in patients with a BMI ≥30 kg/m<sup>2</sup> compared to patients with a lower BMI. In addition, the patch may be less effective in patients weighing ≥90 kg (198 lb).</p>
<p style="text-indent:-2em;margin-left:4em;">• Smoking: Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptives use. This risk increases with age, particularly in patients &gt;35 years of age, and with the number of cigarettes smoked.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Whenever possible, discontinue estrogens at least 4 weeks prior to and through 2 weeks following major surgery or other surgeries known to have an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: When initiating a combination hormonal contraceptive, consider initiating with a monthly bleeding monophasic formulation containing ethinyl estradiol 0.03 to 0.035 mg plus a progestin and adjusting based on adverse reactions and patient preference (Ott 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually transmitted diseases (CDC [Curtis 2016a]; CDC [Curtis 2016b]).</p></div>
<div class="block foc drugH1Div" id="F168376"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xulane: Ethinyl estradiol 35 mcg and norelgestromin 150 mcg per day (1 ea, 3 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zafemy: Ethinyl estradiol 35 mcg and norelgestromin 150 mcg per day (1 ea, 3 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Ethinyl estradiol 35 mcg and norelgestromin 150 mcg per day (1 ea, 3 ea)</p></div>
<div class="block geq drugH1Div" id="F51954305"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F168384"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Norelgestromin-Eth Estradiol Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-35 mcg/24 hrs (per each): $50.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Xulane Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-35 mcg/24 hrs (per each): $50.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch weekly</b> (Zafemy Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150-35 mcg/24 hrs (per each): $50.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866826"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch Weekly, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Evra: Ethinyl estradiol 0.6 mg and norelgestromin 6 mg [releases ethinyl estradiol 35 mcg and norelgestromin 200 mcg per day] (1 ea, 3 ea)</p></div>
<div class="block adip drugH1Div" id="F53566588"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Patches are available in boxes of 3 patches and also in single-patch cartons, intended for use as a replacement patch in case a patch is lost or destroyed.</p></div>
<div class="block admp drugH1Div" id="F52612768"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: New patches should be applied on the same day each week. Apply to clean, dry, intact, healthy skin on the buttock, abdomen, upper outer arm, or back. Avoid areas that will be rubbed by tight clothing. Do not apply to the breasts or to skin that is red, irritated, or cut. Alternate application sites; do not apply to the same place as the previous patch. Do not apply make-up, creams, lotions, powders, or other topical products to the skin where the patch will be placed. Open pouch at top edge and one side edge to remove patch. Remove the patch from the foil pouch, being careful not to remove the clear plastic cover when removing the patch. Discard additional pieces of film above and below the patch. Apply patch by first peeling back half of the clear plastic. Avoid touching the sticky surface of the patch. Apply patch to skin and remove the rest of the liner. Press patch down firmly onto skin using palm of the hand; apply pressure for 10 seconds. Run fingers over entire surface area to smooth out any wrinkles in the patch. The patch should be checked daily to ensure all edges are sticking. When changing the patch each week, the new patch may be applied in the same anatomic area but should be applied to a new spot in that area. Do not use supplemental adhesives or wraps to hold patch into place. Do not cut, damage or alter the size of the patch; contraceptive efficacy may be impaired.</p>
<p style="text-indent:-2em;margin-left:2em;">If a patch becomes partially or completely detached for &lt;24 hours: Try to reapply to same place or replace with a new patch immediately. Do not reapply if patch is no longer sticky, if it is sticking to itself or another surface, or if it has material sticking to it.</p>
<p style="text-indent:-2em;margin-left:2em;">If a patch becomes partially or completely detached for &gt;24 hours (or time period is unknown): Apply a new patch and use this day of the week as the new "patch change day" from this point on. <b>An additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration.</b></p>
<p style="text-indent:-2em;margin-left:2em;">Forgetting to apply the patch at the start of cycle (week 1/day 1): Apply first patch as soon as remembering, using this day of the week as the new "patch change day" from this point on. An additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Forgetting to change patch in the middle of the cycle (week 2/day 8 or week 3/day 15): If &lt;48 hours from normal "patch change day," apply new patch immediately. No backup contraception is needed. If &gt;48 hours from normal "patch change day," apply a new patch and use this day of the week as the new "patch change day" from this point on. An additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Forgetting to remove patch at end of cycle (week 4/day 22): Take off as soon as remembering, start new cycle on usual "patch change day."</p>
<p style="text-indent:-2em;margin-left:2em;">Changing the "patch change day": The "patch change day" can be changed to an earlier day in the week by first completing the current cycle. Then, during the "patch-free interval", select an earlier day to start the new cycle. Shortening the patch-free interval may increase the incidence of spotting or breakthrough bleeding. Do not allow &gt;7 consecutive patch-free days.</p>
<p style="text-indent:-2em;margin-left:2em;">Skin irritation: If patch is in an uncomfortable location, it can be removed and a new patch applied to a different location until the next "patch change day."</p>
<p style="text-indent:-2em;margin-left:2em;">To dispose of patch, fold the sticky sides together and dispose in the trash within a child-resistant container. Do not flush down the toilet.</p></div>
<div class="block adm drugH1Div" id="F168378"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> New patches should be applied on the same day each week. Apply to clean, dry, intact, healthy skin on the buttock, abdomen, upper outer arm, or back. Avoid areas that will be rubbed by tight clothing. Do not apply to the breasts or to skin that is red, irritated, or cut. Alternate application sites; do not apply to the same place as the previous patch. Do not apply make-up, creams, lotions, powders, or other topical products to the skin where the patch will be placed. Open pouch at top edge and one side edge to remove patch. Remove the patch from the foil pouch, being careful not to remove the clear plastic cover when removing the patch. Discard additional pieces of film above and below the patch. Apply patch by first peeling back half of the clear plastic. Avoid touching the sticky surface of the patch. Apply patch to skin and remove the rest of the liner. Press patch down firmly onto skin using palm of the hand; apply pressure for 10 seconds. Run fingers over entire surface area to smooth out any wrinkles in the patch. The patch should be checked daily to ensure all edges are sticking. When changing the patch each week, the new patch may be applied in the same anatomic area but should be applied to a new spot in that area. Do not use supplemental adhesives or wraps to hold patch into place. Do not cut, damage or alter the size of the patch; contraceptive efficacy may be impaired.</p>
<p style="text-indent:0em;margin-top:2em;">If a patch becomes partially or completely detached for &lt;24 hours: Try to reapply to same place or replace with a new patch immediately. Do not reapply if patch is no longer sticky, if it is sticking to itself or another surface, or if it has material sticking to it.</p>
<p style="text-indent:0em;margin-top:2em;">If a patch becomes partially or completely detached for &gt;24 hours (or time period is unknown): Apply a new patch and use this day of the week as the new “patch change day” from this point on. <b>An additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration.</b></p>
<p style="text-indent:0em;margin-top:2em;">Forgetting to apply the patch at the start of cycle (week 1/day 1): Apply first patch as soon as remembering, using this day of the week as the new “patch change day” from this point on. An additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration.</p>
<p style="text-indent:0em;margin-top:2em;">Forgetting to change patch in the middle of the cycle (week 2/day 8 or week 3/day 15): If &lt;48 hours from normal “patch change day,” apply new patch immediately. No back-up contraception is needed. If &gt;48 hours from normal “patch change day,” apply a new patch and use this day of the week as the new “patch change day” from this point on. An additional method of contraception (nonhormonal) must be used for the first 7 days of consecutive administration.</p>
<p style="text-indent:0em;margin-top:2em;">Forgetting to remove patch at end of cycle (week 4/day 22): Take off as soon as remembering, start new cycle on usual “patch change day.”</p>
<p style="text-indent:0em;margin-top:2em;">Changing the “patch change day”: The “patch change day” can be changed to an earlier day in the week by first completing the current cycle. Then, during the “patch-free interval”, select an earlier day to start the new cycle. Shortening the patch free interval may increase the incidence of spotting or breakthrough bleeding. Do not allow &gt;7 consecutive patch-free days.</p>
<p style="text-indent:0em;margin-top:2em;">Skin irritation: If patch is in an uncomfortable location, it can be removed and a new patch applied to a different location until the next “patch change day.”</p>
<p style="text-indent:0em;margin-top:2em;">To dispose of patch, fold the sticky sides together and dispose in the trash within a child-resistant container. Do not flush down the toilet.</p></div>
<div class="block hazard drugH1Div" id="F49132581"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F168393"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at controlled room temperature of 20°C to 25°C (68°F to 77°F); do not refrigerate or freeze.</p></div>
<div class="block usep drugH1Div" id="F53566809"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention of pregnancy (FDA approved in postmenarche pediatric and adult patients).</p></div>
<div class="block mst drugH1Div" id="F56381679"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F168411"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F168370"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Adalimumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: Ethinyl Estradiol-Containing Products may enhance the hepatotoxic effect of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with aprepitant, and to continue back-up contraception for 28 days after discontinuing aprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asparaginase Products: Hormonal Contraceptives may enhance the thrombogenic effect of Asparaginase Products.  Management: Consider discontinuing hormonal contraceptives and using an alternative contraceptive method in patients treated with asparaginase products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May decrease the serum concentration of Hormonal Contraceptives. Management: Use of a high-dose oral contraceptive (at least 30 mcg of ethinyl estradiol combined with norethindrone) is recommended when combined with asunaprevir. Consider an additional barrier method when other forms of contraception are used with asunaprevir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease the serum concentration of Hormonal Contraceptives. Specifically, atazanavir/ritonavir may decrease concentrations of estrogens. Atazanavir may increase the serum concentration of Hormonal Contraceptives. Specifically, atazanavir alone may increase concentrations of estrogens and atazanavir alone or boosted may increase concentrations of progestins. Management: Dose adjustment of hormonal contraceptives or use of alternative or additional nonhormonal contraceptive may be needed when combined with atazanavir. See full interact monograph for details. Atazanavir/cobicistat with drospirenone is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Ethinyl Estradiol-Containing Products. Management: Administer ethinyl estradiol-containing products 4 hours prior to the administration of a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bimekizumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May decrease the serum concentration of Hormonal Contraceptives. Management: Use a non-hormonal contraceptive during brigatinib use and for at least 4 months after the last brigatinib dose. Males with partners of reproductive potential should use contraception during treatment with brigatinib and for 3 months after brigatinib use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carfilzomib: Hormonal Contraceptives may enhance the thrombogenic effect of Carfilzomib.  Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib, especially patients using carfilzomib in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Estrogen Derivatives may enhance the adverse/toxic effect of Chlorprothixene. Estrogen Derivatives may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May decrease the serum concentration of Hormonal Contraceptives. Specifically, cobicistat may decrease serum concentrations of estrogens. Cobicistat may increase the serum concentration of Hormonal Contraceptives. Specifically, cobicistat may increase serum concentrations of progestins. Management: Use alternative or additional nonhormonal forms of contraception when estrogen-containing hormonal contraceptives are combined with cobicistat. Progestin-only contraceptives can be used without back up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May enhance the adverse/toxic effect of Hormonal Contraceptives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Estrogen Derivatives may diminish the diagnostic effect of Cosyntropin.  Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Ethinyl Estradiol-Containing Products may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Weak): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Hormonal Contraceptives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: Ethinyl Estradiol-Containing Products may enhance the hepatotoxic effect of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease the serum concentration of Hormonal Contraceptives. Management: Use a back-up method during coadministration, and to continue back-up contraception for 12 weeks after stopping efavirenz to ensure contraceptive reliability. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: Hormonal Contraceptives may diminish the therapeutic effect of Elagolix. Specifically, estrogen-containing hormonal contraceptives may diminish the therapeutic effects of elagolix. Elagolix may decrease the serum concentration of Hormonal Contraceptives. Specifically, concentrations of progestins may be decreased with elagolix therapy. Elagolix may increase the serum concentration of Hormonal Contraceptives. Specifically, concentrations of ethinyl estradiol may be increased with elagolix therapy.  Management: Use an alternative, nonhormonal contraceptive during treatment with elagolix and for at least 28 days following discontinuation of elagolix treatment. Use of elagolix 200 mg twice daily with an estrogen-containing hormonal contraceptive is not recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: Hormonal Contraceptives may enhance the adverse/toxic effect of Elexacaftor, Tezacaftor, and Ivacaftor. Specifically, the risk for rash may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Hormonal Contraceptives. Specifically, progestin concentrations may decrease. Etravirine may increase the serum concentration of Hormonal Contraceptives. Specifically, estrogen concentrations may increase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exenatide: Hormonal Contraceptives may diminish the therapeutic effect of Exenatide. Exenatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Administer oral hormonal contraceptives at least one hour prior to exenatide. Monitor blood glucose more frequently when patients treated with exenatide initiate therapy with a hormonal contraceptive. Increases in exenatide doses may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing felbamate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Maltol: May decrease the serum concentration of Ethinyl Estradiol-Containing Products. Management: Ferric maltol labeling recommends separating administration of ethinyl estradiol-containing products from ferric maltol by at least four hours to minimize the potential for any interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: Hormonal Contraceptives may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with fosaprepitant, and to continue back-up contraception for 28 days after discontinuing fosaprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: May increase the serum concentration of Ethinyl Estradiol-Containing Products. Management: Ethinyl estradiol daily dose should not exceed 30 mcg during coadministration with fostemsavir. Monitor patients closely for any evidence of a thromboembolism.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: Ethinyl Estradiol-Containing Products may enhance the hepatotoxic effect of Glecaprevir and Pibrentasvir. Glecaprevir and Pibrentasvir may increase the serum concentration of Ethinyl Estradiol-Containing Products.  Management: Use of glecaprevir/pibrentasvir and products containing more than 20 mcg of ethinyl estradiol is not recommended. Lower dose ethinyl estradiol-containing products may be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing griseofulvin to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Estrogen Derivatives may diminish the therapeutic effect of Growth Hormone Analogs.  Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Estrogen Derivatives may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): Estrogen Derivatives may increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: May decrease the serum concentration of Hormonal Contraceptives. Management: Consider alternative methods of contraception (ie, non-hormonal) in patients receiving ivosidenib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: May decrease the serum concentration of Hormonal Contraceptives. More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of hormonal contraceptives. Management: Patients of reproductive potential should use a non-hormonal contraceptive method during treatment with ixazomib and for at least 90 days after the last ixazomib dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactic Acid, Citric Acid, and Potassium Bitartrate: Ethinyl Estradiol may diminish the therapeutic effect of Lactic Acid, Citric Acid, and Potassium Bitartrate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Estrogen Derivatives (Contraceptive) may decrease the serum concentration of LamoTRIgine.  Management: Larger doses of lamotrigine may be needed when combined with estrogens. Specific dosing recommendations vary based on other concomitant medications and which medication is being initiated or discontinued. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lixisenatide: Hormonal Contraceptives may diminish the therapeutic effect of Lixisenatide. Lixisenatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Administer oral hormonal contraceptives 1 hour before or at least 11 hours after administration of lixisenatide. Additionally, monitor blood glucose more frequently when patients treated with lixisenatide initiate therapy with a hormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: Estrogen Derivatives may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 40 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative contraceptive that is not sensitive to CYP3A4 induction or a back-up method during coadministration, and to continue back-up contraception for 4 months after stopping mavacamten to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Estrogen Derivatives may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Estrogen Derivatives may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Hormonal Contraceptives. Management: Nonhormonal contraception should be used during, and for 4 weeks following, mifepristone treatment for hyperglycemia due to Cushing syndrome. If used for pregnancy termination, hormonal contraceptives can be used after pregnancy expulsion is confirmed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitotane: May decrease the serum concentration of Hormonal Contraceptives. Management: Effective nonhormonal contraception is recommended for those of reproductive potential during treatment with mitotane as well as after discontinuation of mitotane for as long as mitotane plasma levels are detectable.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients of childbearing potential who are taking hormonal contraceptives should use an additional form of barrier contraception during treatment with mycophenolate and for 6 weeks after mycophenolate discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Hormonal Contraceptives. Specifically, nirmatrelvir and ritonavir may decrease concentrations of estrogens. Nirmatrelvir and Ritonavir may increase the serum concentration of Hormonal Contraceptives. Specifically, nirmatrelvir and ritonavir may increase concentrations of progestins. Management: Use additional nonhormonal forms of contraception (back-up method) when estrogen-containing hormonal contraceptives are combined with nirmatrelvir/ritonavir. Progestin-only contraceptives can be used without back-up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: May decrease the serum concentration of Hormonal Contraceptives. Management: Women should use an alternative non-hormonal method of contraception or a back-up method when octreotide is combined with hormonal contraceptives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Management: Avoid use of olutasidenib with sensitive or narrow therapeutic index CYP3A4 substrates when possible. If concurrent use with olutasidenib is unavoidable, monitor closely for evidence of decreased concentrations of the CYP3A4 substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing oxcarbazepine to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients should use an alternative, nonhormonal-based form of contraception during the concurrent use of perampanel and for 1 month after discontinuing perampanel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with pitolisant and for at least 21 days after discontinuation of pitolisant treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: Ethinyl Estradiol-Containing Products may decrease serum concentrations of the active metabolite(s) of Proguanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Hormonal Contraceptives. Specifically, protease inhibitors may decrease concentrations of estrogens. Protease Inhibitors may increase the serum concentration of Hormonal Contraceptives. Specifically, protease inhibitors may increase concentrations of progestins. Management: Use alternative or additional nonhormonal forms of contraception when estrogen-containing hormonal contraceptives are combined with protease inhibitors. Progestin-only contraceptives can be used without back up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Estrogen Derivatives may enhance the adverse/toxic effect of Raloxifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: Ethinyl Estradiol-Containing Products may increase serum concentrations of the active metabolite(s) of Roflumilast-Containing Products. Ethinyl Estradiol-Containing Products may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: Ethinyl Estradiol-Containing Products may increase the serum concentration of Selegiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May diminish the therapeutic effect of Hormonal Contraceptives. Management: Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Estrogen Derivatives may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: May decrease the serum concentration of Hormonal Contraceptives. Management: Individuals of childbearing potential should use a non-hormonal contraceptive method during treatment with tazemetostat and for 6 months after. Males with partners of childbearing potential should use contraception during treatment and for 3 months after.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: May decrease the serum concentration of Hormonal Contraceptives. Management: Product labeling recommends that patients taking hormonal contraceptives should use an additional, non-hormonal contraceptive or reliable barrier method during treatment with tetrahydrocannabinol and cannabidiol buccal spray.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Hormonal Contraceptives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients using oral hormonal contraceptives should switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation of tirzepatide and for 4 weeks after each dose escalation of tirzepatide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May enhance the adverse/toxic effect of Estrogen Derivatives (Contraceptive). Specifically, the risk of serious cardiovascular events (eg, stroke, venous thromboembolism, myocardial infarction) may be increased. Management: Avoid cigarette smoking in patients who use estrogen containing contraceptives whenever possible. If combined, monitor for signs and symptoms of serious cardiovascular events (eg, stroke, venous thromboembolism, myocardial infarction).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing topiramate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Hormonal Contraceptives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing meropenem/vaborbactam to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Estrogen Derivatives may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Hormonal Contraceptives may increase the serum concentration of Vitamin K Antagonists. Hormonal Contraceptives may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Hormonal Contraceptives may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Hormonal Contraceptives. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54124387"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in patients with a BMI ≥30 kg/m<sup>2</sup> because the risk of venous thromboembolism (VTE) may be greater compared to patients with a lower BMI. In addition, the patch may be less effective in patients weighing ≥90 kg (≥198 lb).</p>
<p style="text-indent:0em;margin-top:2em;">Due to the increased risk of VTE postpartum, do not initiate combination hormonal contraceptives in any patient &lt;21 days following delivery. The risk decreases to baseline by postpartum day 42. In patients who are between 21 and 42 days after delivery, consider risk factors for VTE (eg, age ≥35 years, previous VTE, thrombophilia, immobility, preeclampsia, transfusion at delivery, cesarean delivery, peripartum cardiomyopathy, BMI ≥30 kg/m<sup>2</sup>, postpartum hemorrhage, smoking) (CDC [Curtis 2016b]). The manufacturer states that combination hormonal contraceptives should not be started until ≥4 weeks after delivery in patients who choose not to breastfeed, or ≥4 weeks after a second trimester abortion or miscarriage.</p>
<p style="text-indent:0em;margin-top:2em;">All available forms of contraception, including combination hormonal contraceptives, can be considered for patients on gender-affirming testosterone therapy after evaluating patient preferences and medical conditions (Bonnington 2020; Krempasky 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Combination hormonal contraceptives may be an option for menstrual suppression in patients who have reached menarche when fewer or no menses are desired (ACOG 2022; SOGC [Kirkham 2019]). Future fertility is not decreased. Base the decision to use a combination hormonal contraceptive or other hormonal preparation on patient preference, their ability to use the method, method effectiveness, potential contraindications, drug interactions, and adverse events. Consider for patients requesting menstrual suppression, including (but not limited to) adolescents, athletes, persons with physical and/or cognitive disabilities, persons on gender-affirming hormone therapy, and persons with limited access to menstrual products or other challenges to hygiene management (ACOG 2022).</p></div>
<div class="block pri drugH1Div" id="F168385"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Use is contraindicated during pregnancy. Combination hormonal contraceptives are used to prevent pregnancy; discontinue if pregnancy occurs. In general, the use of combination hormonal contraceptives, when inadvertently used early in pregnancy, have not been associated with adverse fetal or maternal effects (CDC [Curtis 2016b]).</p></div>
<div class="block mopp drugH1Div" id="F53566800"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Assessment of pregnancy status (prior to therapy), personal or family history of thrombotic or thromboembolic disorders (prior to therapy); BP (prior to therapy and yearly); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potential health status changes at routine visits (CDC [Curtis 2016a]).</p>
<p style="text-indent:-2em;margin-left:2em;">If all doses have not been taken on schedule and 1 menstrual period is missed, the possibility of pregnancy should be considered. If 2 consecutive menstrual periods are missed, assess pregnancy status before a new dosing cycle is started.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patient for vision changes; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.</p></div>
<div class="block pha drugH1Div" id="F168365"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Combination hormonal contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.</p></div>
<div class="block phk drugH1Div" id="F168380"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Topical: Equivalent when applied to abdomen, buttock, upper outer arm, and upper torso</p>
<p style="text-indent:-2em;margin-left:4em;">Ethinyl estradiol and norelgestromin: Rapid; reaches plateau by ~48 hours. Absorption of ethinyl estradiol may be increased with heat exposure due to sauna, whirlpool, or treadmill.</p>
<p style="text-indent:-2em;margin-left:4em;">The AUC plasma concentration of ethinyl estradiol at steady state is ~60% higher following use of the patch than with those observed following an oral 35 mcg tablet. Peak plasma concentrations of ethinyl estradiol are 25% lower with the patch than with the tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding:</p>
<p style="text-indent:-2em;margin-left:4em;">Ethinyl estradiol: Albumin</p>
<p style="text-indent:-2em;margin-left:4em;">Norelgestromin and norgestrel: &gt;97%; norelgestromin to albumin and norgestrel to sex-hormone-binding globulin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Topical: First-pass effect avoided</p>
<p style="text-indent:-2em;margin-left:4em;">Ethinyl estradiol: Forms metabolites</p>
<p style="text-indent:-2em;margin-left:4em;">Norelgestromin: Hepatic to norgestrel and others</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Ethinyl estradiol: ~60% greater using the topical patch when compared to oral tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Ethinyl estradiol: ~17 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Norelgestromin: ~28 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Metabolites of ethinyl estradiol and norelgestromin: Urine and feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F168387"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ortho evra | Xulane | Zafemy</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Evra parches transdermicos</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Evra</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Evra</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USPNF.1">
<a name="USPNF.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23787936">
<a name="23787936"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Gynecology. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. <i>Obstet Gynecol</i>. 2013;122(1):176-185. doi:10.1097/01.AOG.0000431815.52679.bb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/23787936/pubmed" id="23787936" target="_blank">23787936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461694">
<a name="30461694"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 760: dysmenorrhea and endometriosis in the adolescent. <i>Obstet Gynecol</i>. 2018;132(6):e249-e258. doi:10.1097/AOG.0000000000002978<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/30461694/pubmed" id="30461694" target="_blank">30461694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31441825">
<a name="31441825"></a>American College of Obstetricians and Gynecologists. ACOG screening and management of bleeding disorders in adolescents with heavy menstrual bleeding: ACOG committee opinion, number 785. <i>Obstet Gynecol</i>. 2019;134(3):e71-e83. doi:10.1097/AOG.0000000000003411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/31441825/pubmed" id="31441825" target="_blank">31441825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36356248">
<a name="36356248"></a>American College of Obstetricians and Gynecologists’ Committee on Clinical Consensus–Gynecology. General approaches to medical management of menstrual suppression: ACOG clinical consensus no. 3. <i>Obstet Gynecol</i>. 2022;140(3):528-541. doi:10.1097/AOG.0000000000004899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/36356248/pubmed" id="36356248" target="_blank">36356248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32114321">
<a name="32114321"></a>Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer- a systematic review &amp; meta-analysis. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2020;247:163-175. doi:10.1016/j.ejogrb.2020.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/32114321/pubmed" id="32114321" target="_blank">32114321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32304766">
<a name="32304766"></a>Bonnington A, Dianat S, Kerns J, et al. Society of Family Planning clinical recommendations: contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. <i>Contraception</i>. 2020;102(2):70-82. doi:10.1016/j.contraception.2020.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/32304766/pubmed" id="32304766" target="_blank">32304766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23153903">
<a name="23153903"></a>Brahmi D, Curtis KM. When can a woman start combined hormonal contraceptives (CHCs)? A systematic review. <i>Contraception</i>. 2013;87(5):524-538. doi:10.1016/j.contraception.2012.09.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/23153903/pubmed" id="23153903" target="_blank">23153903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29142910">
<a name="29142910"></a>Carswell JM, Roberts SA. Induction and maintenance of amenorrhea in transmasculine and nonbinary adolescents. <i>Transgend Health</i>. 2017;2(1):195-201. doi:10.1089/trgh.2017.0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/29142910/pubmed" id="29142910" target="_blank">29142910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31606136">
<a name="31606136"></a>Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine evidence-based review. <i>Fertil Steril</i>. 2019;112(6):1034-1042. doi:10.1016/j.fertnstert.2019.07.1349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/31606136/pubmed" id="31606136" target="_blank">31606136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31493139">
<a name="31493139"></a>Ciangura C, Coupaye M, Deruelle P, et al; BARIA-MAT group. Clinical practice guidelines for childbearing female candidates for bariatric surgery, pregnancy, and post-partum management after bariatric surgery. <i>Obes Surg</i>. 2019;29(11):3722-3734. doi:10.1007/s11695-019-04093-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/31493139/pubmed" id="31493139" target="_blank">31493139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467319">
<a name="27467319"></a>Curtis KM, Jatlaoui TC, Tepper NK, et al. US selected practice recommendations for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016a;65(4):1‐66. doi: 10.15585/mmwr.rr6504a1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/27467319/pubmed" id="27467319" target="_blank">27467319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467196">
<a name="27467196"></a>Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016b;65(3):1‐103. doi: 10.15585/mmwr.rr6503a1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/27467196/pubmed" id="27467196" target="_blank">27467196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32550522">
<a name="32550522"></a>Damm T, Lamvu G, Carrillo J, Ouyang C, Feranec J. Continuous vs. cyclic combined hormonal contraceptives for treatment of dysmenorrhea: a systematic review. <i>Contracept X</i>. 2019;1:100002. doi:10.1016/j.conx.2019.100002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/32550522/pubmed" id="32550522" target="_blank">32550522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Evra.1">
<a name="Evra.1"></a>Evra (norelgestromin and ethinyl estradiol) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; April 2022</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33109537">
<a name="33109537"></a>Gadducci A, Cosio S, Fruzzetti F. Estro-progestin contraceptives and risk of cervical cancer: a debated issue. <i>Anticancer Res</i>. 2020;40(11):5995-6002. doi:10.21873/anticanres.14620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/33109537/pubmed" id="33109537" target="_blank">33109537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hendeles.1">
<a name="Hendeles.1"></a>Hendeles S, Galand N, Schwers J, “Metabolism of Orally-Administered D-norgestrel in Women,” <i>Acta Endocrinol (Copenh)</i>, 1972, 71(3):557-68.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30638562">
<a name="30638562"></a>Kirkham YA, Ornstein MP, Aggarwal A, McQuillan S. No. 313-menstrual suppression in special circumstances. <i>J Obstet Gynaecol Can</i>. 2019;41(2):e7-e17. doi:10.1016/j.jogc.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/30638562/pubmed" id="30638562" target="_blank">30638562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31394072">
<a name="31394072"></a>Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. <i>Am J Obstet Gynecol</i>. 2020;222(2):134-143. doi:10.1016/j.ajog.2019.07.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/31394072/pubmed" id="31394072" target="_blank">31394072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23235628">
<a name="23235628"></a>Lopez LM, Newmann SJ, Grimes DA, Nanda K, Schulz KF. Immediate start of hormonal contraceptives for contraception. <i>Cochrane Database Syst Rev</i>. 2012;12(12):CD006260. doi:10.1002/14651858.CD006260.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/23235628/pubmed" id="23235628" target="_blank">23235628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33547015">
<a name="33547015"></a>Moreira de Brito C, de Melo ME, Mancini MC, Santo MA, Cercato C. Pharmacokinetics of oral levonorgestrel and ethinylestradiol in women after Roux-en-Y gastric bypass surgery. <i>Surg Obes Relat Dis</i>. 2021;17(4):673-681. doi:10.1016/j.soard.2020.12.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/33547015/pubmed" id="33547015" target="_blank">33547015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6342899">
<a name="6342899"></a>Orme ML, Back DJ, and Breckenridge AM, “Clinical Pharmacokinetics of Oral Contraceptive Steroids,” <i>Clin Pharmacokinet</i>, 1983, 8(2):95-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/6342899/pubmed" id="6342899" target="_blank">6342899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25266435">
<a name="25266435"></a>Ott MA, Sucato GS; Committee on Adolescence. Contraception for adolescents. <i>Pediatrics</i>. 2014;134(4):e1257-1281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/25266435/pubmed" id="25266435" target="_blank">25266435</a>]</span>
<span class="doi">10.1542/peds.2014-2300</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27793376">
<a name="27793376"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Combined hormonal contraception and the risk of venous thromboembolism: a guideline. <i>Fertil Steril</i>. 2017;107(1):43-51. doi:10.1016/j.fertnstert.2016.09.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/27793376/pubmed" id="27793376" target="_blank">27793376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31419378">
<a name="31419378"></a>Shawe J, Ceulemans D, Akhter Z, et al. Pregnancy after bariatric surgery: consensus recommendations for periconception, antenatal and postnatal care. <i>Obes Rev</i>. 2019;20(11):1507-1522. doi:10.1111/obr.12927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/31419378/pubmed" id="31419378" target="_blank">31419378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21538049">
<a name="21538049"></a>Sitruk-Ware R and Nath A, "Metabolic Effects of Contraceptive Steroids," <i>Rev Endocr Metab Disord</i>, 2011, 12(2):63-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/21538049/pubmed" id="21538049" target="_blank">21538049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23153901">
<a name="23153901"></a>Stechna S, Mravcak S, Schultz P, Santolaya J. The quick start contraception initiation method during the 6-week postpartum visit: an efficacious way to improve contraception in federally qualified health centers. <i>Contraception</i>. 2013;88(1):160-163. doi:10.1016/j.contraception.2012.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethinyl-estradiol-and-norelgestromin-pediatric-drug-information/abstract-text/23153901/pubmed" id="23153901" target="_blank">23153901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xulane.1">
<a name="Xulane.1"></a>Xulane (norelgestromin and ethinyl estradiol) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zafemy.1">
<a name="Zafemy.1"></a>Zafemy (norelgestromin and ethinyl estradiol) [prescribing information]. Piscataway, NJ: Amneal Pharmaceuticals LLC; April 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 138807 Version 53.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
